A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

        1 2 3 | Last   [Sort alphabetically]   [Restore default list]

  Subjects -> PHARMACY AND PHARMACOLOGY (Total: 575 journals)
Showing 1 - 200 of 253 Journals sorted by number of followers
Nature Reviews Drug Discovery     Full-text available via subscription   (Followers: 352)
Journal of Clinical Oncology     Hybrid Journal   (Followers: 260)
International Journal of Drug Policy     Hybrid Journal   (Followers: 241)
Journal of Medicinal Chemistry     Hybrid Journal   (Followers: 167)
Drugs     Full-text available via subscription   (Followers: 146)
Journal of Pharmaceutical Sciences     Hybrid Journal   (Followers: 140)
Advanced Drug Delivery Reviews     Hybrid Journal   (Followers: 95)
European Journal of Pharmaceutical Sciences     Hybrid Journal   (Followers: 84)
Drug Safety     Full-text available via subscription   (Followers: 81)
Pharmaceutical Research     Hybrid Journal   (Followers: 69)
Drug Discovery Today     Full-text available via subscription   (Followers: 63)
Biomaterials     Hybrid Journal   (Followers: 54)
Annals of Pharmacotherapy     Hybrid Journal   (Followers: 52)
Clinical Pharmacology & Therapeutics     Hybrid Journal   (Followers: 31)
Pharmacoepidemiology and Drug Safety     Hybrid Journal   (Followers: 29)
AAPS Journal     Hybrid Journal   (Followers: 29)
Annual Review of Pharmacology and Toxicology     Full-text available via subscription   (Followers: 27)
Journal of Pain & Palliative Care Pharmacotherapy     Hybrid Journal   (Followers: 26)
Regulatory Toxicology and Pharmacology     Hybrid Journal   (Followers: 26)
British Journal of Clinical Pharmacology     Hybrid Journal   (Followers: 25)
Journal of Controlled Release     Hybrid Journal   (Followers: 25)
Drug Development and Industrial Pharmacy     Hybrid Journal   (Followers: 25)
International Journal of Pharmacy Practice     Full-text available via subscription   (Followers: 24)
European Journal of Pharmaceutics and Biopharmaceutics     Hybrid Journal   (Followers: 23)
International Journal of Pharmaceutics     Hybrid Journal   (Followers: 23)
Journal of Clinical Psychopharmacology     Hybrid Journal   (Followers: 23)
Journal of Pharmacy and Pharmacology     Full-text available via subscription   (Followers: 23)
Critical Reviews in Toxicology     Hybrid Journal   (Followers: 22)
PharmacoEconomics     Full-text available via subscription   (Followers: 21)
American Journal of Cardiovascular Drugs     Hybrid Journal   (Followers: 20)
Chemical Research in Toxicology     Hybrid Journal   (Followers: 20)
Trends in Pharmacological Sciences     Full-text available via subscription   (Followers: 17)
Clinical Toxicology     Hybrid Journal   (Followers: 17)
Clinical Pharmacokinetics     Full-text available via subscription   (Followers: 16)
Critical Reviews in Clinical Laboratory Sciences     Hybrid Journal   (Followers: 16)
Journal of Natural Products     Hybrid Journal   (Followers: 16)
Journal of Pharmacokinetics and Pharmacodynamics     Hybrid Journal   (Followers: 16)
Toxicology and Applied Pharmacology     Hybrid Journal   (Followers: 16)
Pharmaceutical Development and Technology     Hybrid Journal   (Followers: 16)
Journal of Applied Toxicology     Hybrid Journal   (Followers: 15)
Psychopharmacology     Hybrid Journal   (Followers: 15)
Journal of Clinical Pharmacy and Therapeutics     Hybrid Journal   (Followers: 14)
Journal of Oncology Pharmacy Practice     Hybrid Journal   (Followers: 14)
Journal of the American Pharmacists Association     Full-text available via subscription   (Followers: 14)
Toxicology     Hybrid Journal   (Followers: 14)
International Journal of Toxicology     Hybrid Journal   (Followers: 13)
Journal of Pharmaceutical and Biomedical Analysis     Hybrid Journal   (Followers: 13)
Journal of Pharmacy Practice     Hybrid Journal   (Followers: 13)
Biopharmaceutics and Drug Disposition     Hybrid Journal   (Followers: 12)
Cardiovascular Drugs and Therapy     Hybrid Journal   (Followers: 12)
Clinical Trials     Hybrid Journal   (Followers: 12)
Toxicology Letters     Hybrid Journal   (Followers: 12)
Drug and Chemical Toxicology     Hybrid Journal   (Followers: 12)
American Journal of Therapeutics     Hybrid Journal   (Followers: 11)
Basic & Clinical Pharmacology & Toxicology     Hybrid Journal   (Followers: 11)
European Journal of Clinical Pharmacology     Hybrid Journal   (Followers: 11)
Journal of Psychopharmacology     Hybrid Journal   (Followers: 11)
Pharmacy Education     Full-text available via subscription   (Followers: 11)
Clinical Therapeutics     Hybrid Journal   (Followers: 10)
CNS Drugs     Full-text available via subscription   (Followers: 10)
Pharmaceutical Statistics     Hybrid Journal   (Followers: 10)
Seminars in Oncology Nursing     Full-text available via subscription   (Followers: 10)
Journal of Clinical Pharmacology     Hybrid Journal   (Followers: 10)
Toxicological Sciences     Hybrid Journal   (Followers: 10)
Advances in Pharmacological and Pharmaceutical Sciences     Open Access   (Followers: 10)
Biochemical Pharmacology     Hybrid Journal   (Followers: 9)
ChemMedChem     Hybrid Journal   (Followers: 9)
Drug Metabolism and Disposition     Hybrid Journal   (Followers: 9)
Drugs & Aging     Full-text available via subscription   (Followers: 9)
Drugs & Therapy Perspectives     Full-text available via subscription   (Followers: 9)
Medicinal Chemistry     Hybrid Journal   (Followers: 9)
Seminars in Hematology     Hybrid Journal   (Followers: 9)
Current Opinion in Pharmacology     Hybrid Journal   (Followers: 8)
Current Pharmaceutical Biotechnology     Hybrid Journal   (Followers: 8)
Drug Development Research     Hybrid Journal   (Followers: 8)
Epilepsy Research     Hybrid Journal   (Followers: 8)
European Neuropsychopharmacology     Hybrid Journal   (Followers: 8)
Food Additives & Contaminants Part A     Hybrid Journal   (Followers: 8)
Progress in Neuro-Psychopharmacology and Biological Psychiatry     Hybrid Journal   (Followers: 8)
Toxicology in Vitro     Hybrid Journal   (Followers: 8)
Inhalation Toxicology     Hybrid Journal   (Followers: 8)
Antiviral Research     Hybrid Journal   (Followers: 7)
Current Medicinal Chemistry     Hybrid Journal   (Followers: 7)
Drug Delivery     Open Access   (Followers: 7)
Environmental Toxicology and Pharmacology     Hybrid Journal   (Followers: 7)
Experimental and Clinical Psychopharmacology     Full-text available via subscription   (Followers: 7)
Frontiers in Drug Design & Discovery     Hybrid Journal   (Followers: 7)
Journal of Veterinary Pharmacology and Therapeutics     Hybrid Journal   (Followers: 7)
Prescriber     Hybrid Journal   (Followers: 7)
Toxicology Mechanisms and Methods     Hybrid Journal   (Followers: 7)
Journal of Pharmaceutical Innovation     Hybrid Journal   (Followers: 7)
AAPS PharmSciTech     Hybrid Journal   (Followers: 6)
Biometrical Journal     Hybrid Journal   (Followers: 6)
Clinical Drug Investigation     Full-text available via subscription   (Followers: 6)
Current Drug Delivery     Hybrid Journal   (Followers: 6)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry     Hybrid Journal   (Followers: 6)
Expert Review of Pharmacoeconomics & Outcomes Research     Full-text available via subscription   (Followers: 6)
Human & Experimental Toxicology     Hybrid Journal   (Followers: 6)
Toxicology and Industrial Health     Hybrid Journal   (Followers: 6)
Current Cancer Therapy Reviews     Hybrid Journal   (Followers: 5)
Current Drug Discovery Technologies     Hybrid Journal   (Followers: 5)
Anti-Infective Agents     Hybrid Journal   (Followers: 5)
Current Therapeutic Research     Open Access   (Followers: 5)
Reviews of Physiology, Biochemistry and Pharmacology     Hybrid Journal   (Followers: 5)
Expert Review of Anti-infective Therapy     Full-text available via subscription   (Followers: 5)
Expert Review of Molecular Diagnostics     Full-text available via subscription   (Followers: 5)
Fitoterapia     Hybrid Journal   (Followers: 5)
Journal of Pain Management & Medicine     Open Access   (Followers: 5)
Journal of Cardiovascular Pharmacology and Therapeutics     Hybrid Journal   (Followers: 5)
Journal of Separation Science     Hybrid Journal   (Followers: 5)
Scandinavian Journal of Clinical and Laboratory Investigation     Hybrid Journal   (Followers: 5)
Clinical Research and Regulatory Affairs     Hybrid Journal   (Followers: 5)
Pharmacogenomics Journal     Hybrid Journal   (Followers: 5)
ASSAY and Drug Development Technologies     Hybrid Journal   (Followers: 4)
BioDrugs     Full-text available via subscription   (Followers: 4)
Cancer Chemotherapy and Pharmacology     Hybrid Journal   (Followers: 4)
Current Pharmaceutical Design     Hybrid Journal   (Followers: 4)
Expert Review of Cardiovascular Therapy     Full-text available via subscription   (Followers: 4)
International Journal of Pharmaceutical and Healthcare Marketing     Hybrid Journal   (Followers: 4)
Pharmaceutical Medicine     Full-text available via subscription   (Followers: 4)
Journal of Child and Adolescent Psychopharmacology     Hybrid Journal   (Followers: 4)
Journal of Infection and Chemotherapy     Hybrid Journal   (Followers: 4)
Journal of Labelled Compounds and Radiopharmaceuticals     Hybrid Journal   (Followers: 4)
Journal of Pharmacology and Experimental Therapeutics     Hybrid Journal   (Followers: 4)
Neuropharmacology     Hybrid Journal   (Followers: 4)
Planta Medica     Hybrid Journal   (Followers: 4)
Immunopharmacology and Immunotoxicology     Hybrid Journal   (Followers: 4)
Physiology International     Full-text available via subscription   (Followers: 3)
Archiv der Pharmazie     Hybrid Journal   (Followers: 3)
BMC Pharmacology     Open Access   (Followers: 3)
Cardiovascular Therapeutics     Open Access   (Followers: 3)
Clinical and Experimental Pharmacology and Physiology     Hybrid Journal   (Followers: 3)
CNS Drug Reviews     Open Access   (Followers: 3)
Current Drug Metabolism     Hybrid Journal   (Followers: 3)
Current Pharmacogenomics and Personalized Medicine     Hybrid Journal   (Followers: 3)
Drug Resistance Updates     Hybrid Journal   (Followers: 3)
European Journal of Pharmacology     Hybrid Journal   (Followers: 3)
Frontiers in Medicinal Chemistry     Hybrid Journal   (Followers: 3)
Human Psychopharmacology Clinical and Experimental     Hybrid Journal   (Followers: 3)
Inflammation Research     Hybrid Journal   (Followers: 3)
Investigational New Drugs     Hybrid Journal   (Followers: 3)
Journal of Aerosol Medicine and Pulmonary Drug Delivery     Hybrid Journal   (Followers: 3)
Journal of Cardiovascular Pharmacology     Hybrid Journal   (Followers: 3)
Journal of Ethnopharmacology     Hybrid Journal   (Followers: 3)
Journal of Medical Marketing     Hybrid Journal   (Followers: 3)
Journal of Pharmacological and Toxicological Methods     Hybrid Journal   (Followers: 3)
Microbial Drug Resistance     Hybrid Journal   (Followers: 3)
International Journal of Neuropsychopharmacology     Open Access   (Followers: 3)
Therapeutic Drug Monitoring     Hybrid Journal   (Followers: 3)
Drug Metabolism Reviews     Hybrid Journal   (Followers: 3)
Acta Pharmacologica Sinica     Hybrid Journal   (Followers: 2)
Behavioural Pharmacology     Hybrid Journal   (Followers: 2)
Biomedicine & Pharmacotherapy     Full-text available via subscription   (Followers: 2)
Clinical Neuropharmacology     Hybrid Journal   (Followers: 2)
Current Drug Therapy     Hybrid Journal   (Followers: 2)
Current Enzyme Inhibition     Hybrid Journal   (Followers: 2)
Drugs in R & D     Full-text available via subscription   (Followers: 2)
Inflammopharmacology     Hybrid Journal   (Followers: 2)
Inpharma Weekly     Full-text available via subscription   (Followers: 2)
International Clinical Psychopharmacology     Hybrid Journal   (Followers: 2)
International Immunopharmacology     Hybrid Journal   (Followers: 2)
Letters in Drug Design & Discovery     Hybrid Journal   (Followers: 2)
Medicinal Research Reviews     Hybrid Journal   (Followers: 2)
Pharmacology & Therapeutics     Hybrid Journal   (Followers: 2)
Pharmacology Biochemistry and Behavior     Hybrid Journal   (Followers: 2)
Pharmacopsychiatry     Hybrid Journal   (Followers: 2)
Pulmonary Pharmacology & Therapeutics     Hybrid Journal   (Followers: 2)
Research in Social and Administrative Pharmacy     Hybrid Journal   (Followers: 2)
The Brown University Psychopharmacology Update     Hybrid Journal   (Followers: 2)
Toxicological & Environmental Chemistry     Hybrid Journal   (Followers: 2)
Toxicon     Hybrid Journal   (Followers: 2)
Journal of Microencapsulation: Microcapsules, Liposomes, Nanoparticles, Microcells, Microspheres     Hybrid Journal   (Followers: 2)
Canadian Journal of Physiology and Pharmacology     Hybrid Journal   (Followers: 1)
Current Neuropharmacology     Hybrid Journal   (Followers: 1)
Current Pharmaceutical Analysis     Hybrid Journal   (Followers: 1)
Current Vascular Pharmacology     Hybrid Journal   (Followers: 1)
Fundamental & Clinical Pharmacology     Hybrid Journal   (Followers: 1)
Journal of Drug Targeting     Hybrid Journal   (Followers: 1)
Journal of Inflammation     Open Access   (Followers: 1)
Journal of Neuroimmune Pharmacology     Hybrid Journal   (Followers: 1)
Journal of Texture Studies     Hybrid Journal   (Followers: 1)
Pharmacogenetics and Genomics     Hybrid Journal   (Followers: 1)
Particulate Science and Technology: An International Journal     Hybrid Journal   (Followers: 1)
Pharmaceutical Biology     Open Access  
Journal of Liposome Research     Hybrid Journal  
Vascular Pharmacology     Hybrid Journal  
Toxin Reviews     Hybrid Journal  
Kaohsiung Journal of Medical Sciences     Open Access  
Redox Report     Open Access  
Pharmacological Research     Hybrid Journal  
PharmacoEconomics & Outcomes News     Full-text available via subscription  
Pharmaceutical Chemistry Journal     Hybrid Journal  
NeuroMolecular Medicine     Hybrid Journal  
Journal of Ocular Pharmacology and Therapeutics     Hybrid Journal  
Harm Reduction Journal     Open Access  
Current Nanoscience     Hybrid Journal  
Infectious Disorders - Drug Targets     Hybrid Journal  
Current Bioactive Compounds     Hybrid Journal  
Cancer Biotherapy & Radiopharmaceuticals     Hybrid Journal  
Autonomic & Autacoid Pharmacology     Hybrid Journal  

        1 2 3 | Last   [Sort alphabetically]   [Restore default list]

Similar Journals
Journal Cover
Therapeutic Drug Monitoring
Journal Prestige (SJR): 0.656
Citation Impact (citeScore): 2
Number of Followers: 3  
 
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 0163-4356 - ISSN (Online) 1536-3694
Published by LWW Wolters Kluwer Homepage  [330 journals]
  • Quantification of Efavirenz Hydroxymetabolites in Human Plasma Using
           LC-HRMS/MS

    • Free pre-print version: Loading...

      Authors: Pettersson Bergstrand; Madeleine; Soeria-Atmadja, Sandra; Barclay, Victoria; Tolic, Jelena; Navér, Lars; Gustafsson, Lars L.; Pohanka, Anton
      Abstract: imageBackground: Efavirenz (EFV) is a drug used to treat HIV. Low plasma concentrations of EFV result in suboptimal viral suppression, whereas high concentrations can cause adverse neuropsychiatric side reactions. Some studies have identified a correlation between the plasma concentrations of EFV metabolites and neurotoxicity. To our knowledge, no studies have investigated the metabolism of EFV in young children and its effect on treatment outcomes. Therefore, the aim of this study was to develop and validate a method for quantifying EFV and its metabolites in human plasma derived from children.Methods: Sample preparation was performed using protein precipitation of 100 µL plasma. Thereafter, an aliquot of the supernatant was used to quantify EFV, 7-hydroxyefavirenz (7-OH-EFV), 8-hydroxyefavirenz (8-OH-EFV), and a newly discovered metabolite (“EFAdeg”) associated with 8-OH-EFV. A second aliquot of the supernatant was hydrolyzed using β-glucuronidase/arylsulfatase and used with the first aliquot to quantify phase II metabolites. The analyses were performed using a Dionex Ultimate 3000RS LC-system coupled with a Q Exactive Orbitrap mass spectrometer.Results: The method has a measuring range of 100–50,000 ng/mL (EFV, 8-OH-EFV), 125–25,000 ng/mL (7-OH-EFV), and 200–10,000 ng/mL (“EFAdeg”). All criteria of the European Medicines Agency guidelines regarding precision, accuracy, and selectivity were met. Of note, carryover must be considered for 8-OH-EFV. Overall, the validated method was successfully applied to plasma samples obtained from children and confirmed the presence of the newly discovered metabolite, “EFAdeg.”Conclusions: An LC-HRMS/MS method for the quantification of EFV and its phase I and II metabolites was developed and validated. This method is suitable for analyzing plasma samples from children. Furthermore, studies using this method identified an additional metabolite that may influence the concentration of 8-OH-EFV in patient samples.
      PubDate: Tue, 11 Jun 2024 00:00:00 GMT-
       
  • Medication Adherence Monitoring Using Alternative Sample Matrices:
           Bridging the Gap Between Analytical Validation and Clinical Interpretation
           

    • Free pre-print version: Loading...

      Authors: Zijp; Tanja R.; Izzah, Zamrotul; Touw, Daan J.; van Boven, Job F. M.
      Abstract: imageNo abstract available
      PubDate: Fri, 07 Jun 2024 00:00:00 GMT-
       
  • Efficacy and Safety of Programmed Death 1/Programmed Death-Ligand 1 Plus
           Cytotoxic T-Lymphocyte–Associated Antigen 4 Inhibitors for Advanced or
           Metastatic Non–Small Cell Lung Cancer: A Meta-analysis Based on
           Randomized Controlled Trials

    • Free pre-print version: Loading...

      Authors: Ren; Wei; Fang, Yingying; He, Yujing; Ren, Yifeng; Wang, Minfang; Xu, Anyi; Ruan, Jiale; Tao, Qinghua
      Abstract: imageBackground: This meta-analysis aims to investigate the efficacy and safety of programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) combined with cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) inhibitors for patients with advanced or metastatic non-small cell lung cancer (NSCLC).Methods:
      Authors conducted a comprehensive search of PubMed, Embase, Cochrane Library, Web of Science, Scopus, and Medline for randomized controlled trials comparing the prognosis and safety of PD-1/PD-L1 plus CTLA-4 inhibitors with other therapies for advanced or metastatic NSCLC. Hazard ratios (HRs) and 95% confidence intervals (CIs) were used as effect sizes. The primary outcomes of this study were overall survival (OS) and progression-free survival.Results: A total of 4943 patients diagnosed with stage III/IV advanced or metastatic NSCLC were included in the analysis of the 6 randomized controlled trials. The results showed that patients receiving dual immunotherapy with PD-1/PD-L1 plus CTLA-4 inhibitors had a longer survival time compared with the control group (HR = 0.88, P = 0.044). However, no statistically significant difference was observed in progression-free survival (HR = 0.95, P = 0.579). Subgroup analysis revealed better OS in the interventional group for patients aged>65 years (HR = 0.88, P = 0.076), smokers (HR = 0.81, P = 0.036), and those with a tumor mutational burden (TMB) ≥20 mut/Mb (HR = 0.66, P < 0.001). Conversely, the control group demonstrated superior OS in patients with TMB
      PubDate: Thu, 06 Jun 2024 00:00:00 GMT-
       
  • Catching the Culprit: Benzylpenicillin Neurotoxicity Confirmed by
           Therapeutic Drug Monitoring in a Critically Ill Patient With Continuous
           Venovenous Hemofiltration

    • Free pre-print version: Loading...

      Authors: van Gelder; Thomas G.; Schweitzer, Valentijn A.; Uijtendaal, Esther V.; Sikma, Maaike A.
      Abstract: imageAbstract: We present the case of a 65-year-old patient who was treated with high-dose benzylpenicillin for severe invasive pneumococcal pneumonia, complicated by acute renal failure managed with continuous venovenous hemofiltration. After cessation of continuous venovenous hemofiltration, the patient experienced multiple tonic–clonic seizures. Therapeutic drug monitoring revealed high total serum concentrations of benzylpenicillin, identifying it as the likely cause of the neurotoxicity. This case study presents the first documented total serum benzylpenicillin concentration associated with neurotoxicity.
      PubDate: Thu, 06 Jun 2024 00:00:00 GMT-
       
  • Fluorescence-Based Lateral Flow Immunoassay for Quantification of
           Infliximab: Analytical and Clinical Performance Evaluation

    • Free pre-print version: Loading...

      Authors: Kim; Eun Sil; Chon, Hyangah; Kwon, Yiyoung; Lee, Misook; Kim, Mi Jin; Choe, Yon Ho
      Abstract: imageBackground: Therapeutic drug monitoring of infliximab (IFX) can improve treatment outcomes; however, the temporal gap between drug concentration monitoring and subsequent availability restricts its practical application. To address this issue, an automated monitoring method, AFIAS IFX, was developed to rapidly and accurately analyze IFX concentration in blood. The analytical and clinical performances of this method were assessed to establish its clinical utility.Methods: The analytical performance of AFIAS IFX was evaluated according to Clinical and Laboratory Standard Institute guidelines. For clinical validation, AFIAS IFX was compared with 3 established enzyme-linked immunosorbent assay kits (LISA TRACKER, RIDASCREEN, and ImmunoGuide) using 100 consecutive samples from 28 patients treated with IFX. Passing–Bablok regression and Bland–Altman analyses were performed to compare the methods.Results: The detection and quantification limits of AFIAS IFX were 0.12 and 0.20 mcg/mL, respectively. Furthermore, AFIAS IFX analyzed samples within 10 minutes for concentrations up to 50 mcg/mL, exhibiting reproducibility (coefficient of variation [CV] ≤7.8%) and accuracy (recovery 98%–101%) with serum, plasma, and whole blood samples. Clinically, it exhibited a good correlation with the 3 established enzyme-linked immunosorbent assay kits. For patients treated with Remicade (IFX), the Passing–Bablok regression slope was 1.001–1.259, with a mean difference of −1.48 to 0.28 mcg/mL. For patients treated with CT-P13, the Passing–Bablok regression slope was 0.974–1.254, with a mean difference of −2.44 to 0.15 mcg/mL.Conclusions: AFIAS IFX, a novel fluorescence-based lateral flow assay, exhibited excellent performance in analyzing IFX trough levels and is a potentially powerful tool for therapeutic drug monitoring in clinical settings, with opportunities for further development.
      PubDate: Wed, 15 May 2024 00:00:00 GMT-
       
  • Management of the Drug–Drug Interactions Between Valproic Acid and
           Dolutegravir—A Case Study

    • Free pre-print version: Loading...

      Authors: Cattaneo; Dario; Giacomelli, Andrea; Calvagna, Nunziata; Bonini, Igor; Ridolfo, Anna Lisa; Gervasoni, Cristina
      Abstract: Objective: Preliminary evidence shows that concomitant administration of valproic acid can reduce the exposure to dolutegravir with limited clinical impacts. Here, we describe a male living with HIV who experienced a drastic reduction in dolutegravir trough concentrations a few weeks after starting valproic acid treatment as identified by therapeutic drug monitoring. Concomitantly, pharmacists recommended a supplementation of magnesium to improve insomnia.Case report: A 62-year-old man with HIV on antiretroviral therapy with dolutegravir and lamivudine recently added valproic acid to clonazepam and sertraline to treat severe sleep disturbances. An 84% reduction in dolutegravir trough concentrations was observed compared with the previous outpatient visit (418 versus 2714 ng/mL), with values close to the minimum effective drug concentration (300 ng/mL). Considering this, we strongly discourage the use of magnesium.Conclusions: We are confident that our findings can contribute to a better understanding of the clinical problems that infectious disease physicians encounter in their daily management of people with HIV and how therapeutic drug monitoring may add value in this context. This case also highlights the importance of multidisciplinary services for the optimal management of polypharmacy in people with HIV.
      PubDate: Tue, 14 May 2024 00:00:00 GMT-
       
  • Evaluation of Published Population Pharmacokinetic Models to Inform
           Tacrolimus Therapy in Adult Lung Transplant Recipients

    • Free pre-print version: Loading...

      Authors: Kirubakaran; Ranita; Singh, Rani M.; Carland, Jane E.; Day, Richard O.; Stocker, Sophie L.
      Abstract: imageBackground: The applicability of currently available tacrolimus population pharmacokinetic models in guiding dosing for lung transplant recipients is unclear. In this study, the predictive performance of relevant tacrolimus population pharmacokinetic models was evaluated for adult lung transplant recipients.Methods: Data from 43 lung transplant recipients (1021 tacrolimus concentrations) administered an immediate-release oral formulation of tacrolimus were used to evaluate the predictive performance of 17 published population pharmacokinetic models for tacrolimus. Data were collected from immediately after transplantation up to 90 days after transplantation. Model performance was evaluated using (1) prediction-based assessments (bias and imprecision) of individual predicted tacrolimus concentrations at the fourth dosing based on 1 to 3 previous dosings and (2) simulation-based assessment (prediction-corrected visual predictive check; pcVPC). Both assessments were stratified based on concomitant azole antifungal use. Model performance was clinically acceptable if the bias was within ±20%, imprecision was ≤20%, and the 95% confidence interval of bias crossed zero.Results: In the presence of concomitant antifungal therapy, no model showed acceptable performance in predicting tacrolimus concentrations at the fourth dosing (n = 33), and pcVPC plots displayed poor model fit to the data set. However, this fit slightly improved in the absence of azole antifungal use, where 4 models showed acceptable performance in predicting tacrolimus concentrations at the fourth dosing (n = 33).Conclusions: Although none of the evaluated models were appropriate in guiding tacrolimus dosing in lung transplant recipients receiving concomitant azole antifungal therapy, 4 of these models displayed potential applicability in guiding dosing in recipients not receiving concomitant azole antifungal therapy. However, further model refinement is required before the widespread implementation of such models in clinical practice.
      PubDate: Thu, 09 May 2024 00:00:00 GMT-
       
  • Prevalence of Psychoactive Substance Use During Pregnancy in Argentine
           Women: A Pilot Study Testing Maternal Hair

    • Free pre-print version: Loading...

      Authors: Vieiros; Melina; Mirahi, Afrouz; Villarreal, Marina; Ramos-Triguero, Anna; Fernández-Rubal, Iria; Andreu-Fernández, Vicente; Pichini, Simona; García-Algar, Óscar; Marchei, Emilia
      Abstract: imageBackground: The use of psychoactive substances (PSs) during pregnancy is a major public health concern because of their increasing prevalence worldwide. This study examined the understudied issue of gestational PS consumption in a cohort of Argentine delivering mothers.Methods: A cross-sectional pilot study involving 51 women receiving delivery care was conducted at the Santa Rosa Hospital in La Pampa, Argentina. Information on maternal sociodemographic characteristics, pregnancy history, and drug use was obtained through standardized interviews. Maternal hair samples were analyzed for alcohol, tobacco, licit, illicit, and prescription substance biomarkers using ultra-high-performance liquid chromatography high-resolution mass spectrometry and gas chromatography mass spectrometry.Results: During pregnancy, 49.0% of participants reported alcohol consumption, 25.5% reported tobacco use, and 23.5% reported cannabis use. Hair samples from 56.9% of the women were positive for illicit PSs, with the most frequent being cocaine (41.2%) and cannabis (15.7%). Among the women, 47.1% consumed alcohol during pregnancy. Of the 24 women with hair ethyl glucuronide ≥5 pg/mg, 33.3% drank until the end of gestation and 58.3% started a social drinking habit in the second half. The analysis also detected prescription substances (anticonvulsants, antidepressants, methadone, opioids, antihistamines, antiemetics, and analgesics), caffeine (70.6%), lidocaine, and levamisole, some of which were cocaine or opioid adulterants.Conclusions: This is the first study to objectively assess the consumption of licit and illicit PSs during pregnancy in Argentina. In contrast to most nearby countries, cocaine was the most detected illicit PS in this cohort of Argentine delivering women. This finding highlights the importance of regular monitoring of local trends in PS use during pregnancy.
      PubDate: Tue, 07 May 2024 00:00:00 GMT-
       
  • Daptomycin Exposure Prediction With a Limited Sampling Strategy

    • Free pre-print version: Loading...

      Authors: De Gregori; Simona; Seminari, Elena; Capone, Mara; Giordani, Paola; Bruno, Raffaele; De Silvestri, Annalisa
      Abstract: imageBackground: Daptomycin is a cyclic lipopeptide antibiotic used to treat serious infectious endocarditis caused by Staphylococcus aureus. The pharmacodynamic parameter correlating best with efficacy is the ratio of the estimated area under the concentration (AUC0-24)–time curve to the minimum inhibitory concentration. The aim of the study is to develop a limited sampling strategy to estimate AUC0-24 using a reduced number of samples.Methods: Sixty-eight daptomycin AUC0-24 values were calculated for 50 White patients who underwent treatment for at least 5 consecutive days. Plasma concentrations were detected using a validated high-performance liquid chromatography–tandem mass spectrometry analytical method, with daptomycin-d5 as an internal standard. Multiple regression was used to evaluate the ability of 2 concentration–time points to predict the AUC0-24 calculated from the entire pharmacokinetic profile. Prediction bias was calculated as the mean prediction error, whereas prediction precision was estimated as the mean absolute prediction error. The development and validation datasets comprised 40 and 10 randomly selected patients, respectively.Results: The AUC0-24 (mg*h/L) was best estimated using the daptomycin trough concentration and plasma concentrations detected 2 hours after dosing. We calculated a mean prediction error of 1.6 (95% confidence interval, −10.7 to 10.9) and a mean absolute prediction error of 11.8 (95% confidence interval, 5.3–18.3), with 73% of prediction errors within ±15%.Conclusions: An equation was developed to estimate daptomycin exposure (AUC0-24), offering clinical applicability and utility in generating personalized dosing regimens, especially for individuals at high risk of treatment failure or delayed response.
      PubDate: Thu, 25 Apr 2024 00:00:00 GMT-
       
  • Tacrolimus Monitoring in Liver Transplant Recipients, Posttransplant
           Cholestasis: A Comparative Between 2 Commercial Immunoassays and a Liquid
           Chromatography-Tandem Mass Spectrometry Method

    • Free pre-print version: Loading...

      Authors: Parant; François; Delignette, Marie-Charlotte; Charpiat, Bruno; Lacaille, Louis; Lebosse, Fanny; Monneret, Guillaume; Mohkam, Kayvan; Mabrut, Jean-Yves; Aubrun, Frederic; Heyer, Laurent; Antonini, Teresa
      Abstract: imageBackground: Cholestasis commonly occurs after orthotopic liver transplantation. It can be extrahepatic because of mechanical obstruction or intrahepatic because of various causes. During cholestasis episodes, blood concentrations of tacrolimus (TAC) metabolites may increase, potentially affecting TAC concentrations measured by immunoassays. This study aimed to simultaneously evaluate the analytical performance of 2 TAC immunoassays, a quantitative microsphere system (QMS) immunoassay, and chemiluminescence microparticle immunoassay, using liquid chromatography-tandem mass spectrometry (LC-MS/MS) as a reference method in liver transplant recipients.Methods: This single-center study included 265 patients who underwent orthotopic liver transplantation. In total, 942 blood samples were collected. TAC trough concentrations were measured using LC-MS/MS and 2 immunoassays in parallel. The plasma concentrations of conjugated bilirubin were measured in all samples. The results were analyzed using Bland–Altman plots and Passing–Bablok regressions.Results: The Bland–Altman plot analysis showed that the TAC QMS immunoassay has a significant bias (+37%) compared with LC-MS/MS, and this bias was higher in patients with cholestasis with hyperbilirubinemia (≤+70% in patients with conjugated bilirubin>150 µmol/L). In comparison, the chemiluminescence microparticle immunoassay showed acceptable analytical performance in patients with hyperbilirubinemia (bias
      PubDate: Fri, 19 Apr 2024 00:00:00 GMT-
       
  • Influence of Tacrolimus Intrapatient Variability on Allograft Rejection
           Frequency and Survival Following Liver Transplantation

    • Free pre-print version: Loading...

      Authors: Soares; Maria Eduarda; Costa, Gabriela; Guerra, Laura; Morais, Maria Clara; Vaz, Nayana; Codes, Liana; Bittencourt, Paulo Lisboa
      Abstract: imageBackground: Tacrolimus is the primary calcineurin inhibitor used in immunosuppressive regimens to prevent allograft rejection (AR) after organ transplantation. Recent studies have linked intrapatient variability (IPV) of tacrolimus with AR occurrence and reduced survival, especially in kidney transplant recipients. However, limited data are available on the impact of tacrolimus IPV on adverse outcomes after liver transplantation (LT).Aims: The aim of this study was to assess the association between tacrolimus IPV using various methodologies with acute AR and long-term patient survival after LT.Methods: All patients who underwent LT from January 2010 to July 2021 were retrospectively evaluated. Tacrolimus IPV was calculated for each patient using the mean and SD, mean absolute deviation (MAD), coefficient of variation (CV), and time in therapeutic range (TTR). These measures were then compared with AR within the first 24 months after LT and to long-term survival.Results: Out of 234 patients, 32 (13.7%) developed AR and 183 (78.2%) survived, with a mean follow-up of 101 ± 43 months. Tacrolimus IPV, assessed by mean, SD, MAD, and CV, was 8.3 ± 2.1, 2.7 ± 1.3, 32.0% ± 11.7%, and 39.4% ± 15.4%, respectively. There was no statistically significant correlation between Tacrolimus IPV and AR or survival post-LT.Conclusions: In a large cohort of patients from diverse racial backgrounds, tacrolimus IPV was not associated with clinically relevant outcomes such as AR and survival after LT.
      PubDate: Fri, 29 Mar 2024 00:00:00 GMT-
       
  • Age-Related Changes in Vancomycin Protein Binding: Is It Time to Take It
           Seriously'

    • Free pre-print version: Loading...

      Authors: Gadsby; Jessica; Stachow, Lucy; Mulla, Hussain
      Abstract: imageBackground: Vancomycin (VAN) protein binding in plasma is influenced by illness and age; hence, doses titrated according to total concentrations are fraught. In this study, model-estimated free VAN concentrations (EFVC) were compared with assumed free VAN concentrations (AFVC) in neonates, children, and adults in the intensive care unit and those on dialysis.Methods: Patient cohorts were identified from the hospital database. Demographics, clinical characteristics, total VAN concentrations, and laboratory variables were obtained from electronic health records. EFVC was derived from 6 models identified in the literature. For all models, total VAN concentration was the most important predictor; other predictors included albumin, total protein, and dialysis status. The AFVC was calculated as 50% of the total concentration (ie, assumption of 50% bound).Results: Differences between EFVC and AFVC in adults were insignificant; however, differences in pediatric intensive care unit patients, according to 2 different models, were significant: mean ± SD = 4.1 ± 1.58 mg/L and 4.7 ± 2.46 mg/L (P < 0.001); the percentages within the free VAN trough range = 30.4% versus 55.1% and 30% versus 55.1%; and the supratherapeutic percentages = 65.2% versus 31.9% and 66.7% versus 31.9%, respectively. In neonates, the difference between EFVC and AFVC was mean ± SD = 6.9 ± 1.95 mg/L (P < 0.001); the percentages within the free VAN trough range for continuous and intermediate dosing were 0% versus 81.3% and 14.3% versus 71.4%, and the supratherapeutic percentages were 100% versus 6.25% and 71.4% versus 0%, respectively.Conclusions: The fraction of free unbound VAN is higher in sick children and neonates than in adults. Therefore, total VAN concentrations do not correlate with the pharmacologically active free VAN concentrations in the same manner as in adults. Adjusting VAN doses in neonates and children to target the same total VAN concentration as the recommended therapeutic range for adults may result in toxicfree concentrations.
      PubDate: Fri, 29 Mar 2024 00:00:00 GMT-
       
  • Changes in Perampanel Pharmacokinetics and Cytochrome P450 3A4 Activity
           Before, During, and After Pregnancy

    • Free pre-print version: Loading...

      Authors: Yamamoto; Yoshiaki; Akita, Naoto; Nogimoto, Hiroki; Suzuki, Wakana; Imai, Katsumi; Takahashi, Yukitoshi; Kagawa, Yoshiyuki
      Abstract: imageAbstract: This study evaluated perampanel pharmacokinetics and cytochrome P450 3A4 (CYP3A4) activity, assessed using the level of 4β-hydroxycholesterol (4β-OHC) as an endogenous biomarker of CYP3A4, before, during, and after pregnancy in a woman with epilepsy and compared these measurements with those from a control group of nonpregnant women with epilepsy. A 21-year-old pregnant woman was being treated with perampanel (serum concentration: 1120 ng/mL), lacosamide, and lamotrigine. After the first trimester, the lamotrigine concentration decreased markedly; however, the perampanel concentration remained almost unchanged (range, 1130–1320 ng/mL). Similarly, serum 4β-OHC levels did not change during pregnancy (before pregnancy, 78.2 ng/mL; during pregnancy, 62.2–83.2 ng/mL). To compare these measurements with those in nonpregnant women, we enrolled 27 nonpregnant women with epilepsy (age range, 16–40 years). In the control patients, we found a strong negative correlation between the concentration-to-dose ratio of perampanel and the 4β-OHC level (r = −0.78, P < 0.001). As there was no significant change in CYP3A4 activity, we concluded that the serum perampanel concentration did not change significantly before, during, or after pregnancy. More patients need to be studied to confirm these early results.
      PubDate: Tue, 26 Mar 2024 00:00:00 GMT-
       
  • Monitoring of Tissue and Plasma Imipenem Concentrations for the Treatment
           of Necrotizing Fasciitis With Carbapenem-Resistant Enterobacteriaceae—A
           Letter to the Editor

    • Free pre-print version: Loading...

      Authors: Dufraigne; Antonin; Perinel-Ragey, Sophie; Guitton, Jérôme; Cohen, Sabine; Thiery, Guillaume; Launay, Manon
      Abstract: imageNo abstract available
      PubDate: Tue, 26 Mar 2024 00:00:00 GMT-
       
  • Probe Electrospray Ionization Tandem Mass Spectrometry for the Detection
           and Quantification of Benzodiazepines

    • Free pre-print version: Loading...

      Authors: Griffeuille; Pauline; El Balkhi, Souleiman; Dulaurent, Sylvain; Saint-Marcoux, Franck
      Abstract: imageBackground: Legally prescribed benzodiazepines (BZDs) and designer BZDs are widely misused and must be determined in multiple contexts (eg, overdose, drug-facilitated sexual assaults, or driving under the influence of drugs). This study aimed to develop a method for measuring serum BZD levels using probe electrospray ionization (PESI) mass spectrometry and an isotope dilution approach.Methods: A tandem mass spectrometer equipped with a probe electrospray ionization source in multiple reaction monitoring mode was used. Isotope dilution was applied for quantification using a deuterated internal standard at a fixed concentration for alprazolam, bromazepam, diazepam, nordiazepam, oxazepam, temazepam, zolpidem, and zopiclone. This method included designer BZDs: clonazolam, deschloroetizolam, diclazepam, etizolam, flualprazolam, flubromazepam, flubromazolam, meclonazepam, nifoxipam, and pyrazolam. Sample preparation was done by mixing 10 µL of serum with 500 µL of an ethanol/ammonium formate 0.01 mol/L buffer. Complete validation was performed, and the method was compared with liquid chromatography coupled with mass spectrometry (LC-MS/MS) and immunoassays (IC) by analyzing 40 real samples.Results: The analysis time for identification and quantification of the 18 molecules was 2.5 minutes. This method was fully validated, and the limits of quantification varied from 5 to 50 mcg/L depending on the molecule. In the 40 real samples, 100% of molecules (n = 89) were detected by both LC-MS/MS and PESI-MS/MS, and regression analysis showed excellent agreement between the 2 methods (r2 = 0.98). On IC, bromazepam and zolpidem were not detected in 2 and 1 cases, respectively.Conclusions: PESI-MS/MS allows serum BZD detection and measurement. Given the isotope dilution approach, a calibration curve was not required, and its performance was similar to that of LC-MS/MS, and its specificity was higher than that of IC.
      PubDate: Mon, 18 Mar 2024 00:00:00 GMT-
       
  • Salivary Therapeutic Monitoring of Buprenorphine in Neonates After
           Maternal Sublingual Dosing Guided by Physiologically Based Pharmacokinetic
           Modeling

    • Free pre-print version: Loading...

      Authors: Alsmadi; Mo'tasem M.
      Abstract: imageBackground: Opioid use disorder (OUD) during pregnancy is associated with high mortality rates and neonatal opioid withdrawal syndrome (NOWS). Buprenorphine, an opioid, is used to treat OUD and NOWS. Buprenorphine active metabolite (norbuprenorphine) can cross the placenta and cause neonatal respiratory depression (EC50 = 35 ng/mL) at high brain extracellular fluid (bECF) levels. Neonatal therapeutic drug monitoring using saliva decreases the likelihood of distress and infections associated with frequent blood sampling.Methods: An adult physiologically based pharmacokinetic model for buprenorphine and norbuprenorphine after intravenous and sublingual administration was constructed, vetted, and scaled to newborn and pregnant populations. The pregnancy model predicted that buprenorphine and norbuprenorphine doses would be transplacentally transferred to the newborns. The newborn physiologically based pharmacokinetic model was used to estimate the buprenorphine and norbuprenorphine levels in newborn plasma, bECF, and saliva after these doses.Results: After maternal sublingual administration of buprenorphine (4 mg/d), the estimated plasma concentrations of buprenorphine and norbuprenorphine in newborns exceeded the toxicity thresholds for 8 and 24 hours, respectively. However, the norbuprenorphine bECF levels were lower than the respiratory depression threshold. Furthermore, the salivary buprenorphine threshold levels in newborns for buprenorphine analgesia, norbuprenorphine analgesia, and norbuprenorphine hypoventilation were observed to be 22, 2, and 162 ng/mL.Conclusions: Using neonatal saliva for buprenorphine therapeutic drug monitoring can facilitate newborn safety during the maternal treatment of OUD using sublingual buprenorphine. Nevertheless, the suitability of using adult values of respiratory depression EC50 for newborns must be confirmed.
      PubDate: Fri, 16 Feb 2024 00:00:00 GMT-
       
  • Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20,
           and Letrozole in Human Plasma: A Novel LC-MS/MS Method

    • Free pre-print version: Loading...

      Authors: Posocco; Bianca; Zanchetta, Martina; Orleni, Marco; Gagno, Sara; Montico, Marcella; Peruzzi, Elena; Roncato, Rossana; Gerratana, Lorenzo; Corsetti, Serena; Puglisi, Fabio; Toffoli, Giuseppe
      Abstract: imageBackground: Therapeutic drug monitoring (TDM) using cyclin-dependent kinase inhibitors (CDK4/6is) is a novel approach for optimizing treatment outcomes. Currently, palbociclib, ribociclib, and abemaciclib are the available CDK4/6is and are primarily coadministered with letrozole. This study aimed to develop and validate an LC-MS/MS method for the simultaneous analysis of CDK4/6is, 2 active metabolites of abemaciclib (M2 and M20), and letrozole in human plasma for use in TDM studies.Methods: Sample pretreatment comprised protein precipitation with methanol and dilution of the supernatant with an aqueous mobile phase. Chromatographic separation was achieved using a reversed-phase XBridge BEH C18 column (2.5 μm, 3.0 × 75 mm XP), with methanol serving as the organic mobile phase and pyrrolidine–pyrrolidinium formate (0.005:0.005 mol/L) buffer (pH 11.3) as the aqueous mobile phase. A triple quadrupole mass spectrometer was used for the detection, with the ESI source switched from negative to positive ionization mode and the acquisition performed in multiple reaction monitoring mode.Results: The complete validation procedure was successfully performed in accordance with the latest regulatory guidelines. The following analytical ranges (ng/mL) were established for the tested compounds: 6–300, palbociclib and letrozole; 120–6000, ribociclib; 40–800, abemaciclib; and 20–400, M2 and M20. All results met the acceptance criteria for linearity, accuracy, precision, selectivity, sensitivity, matrix effects, and carryover. A total of 85 patient samples were analyzed, and all measured concentrations were within the validated ranges. The percent difference for the reanalyzed samples ranged from −11.2% to 7.0%.Conclusions: A simple and robust LC-MS/MS method was successfully validated for the simultaneous quantification of CDK4/6is, M2, M20, and letrozole in human plasma. The assay was found to be suitable for measuring steady-state trough concentrations of the analytes in patient samples.
      PubDate: Tue, 06 Feb 2024 00:00:00 GMT-
       
  • Analytical Validation of a Volumetric Absorptive Microsampling Method for
           Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents,
           Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib,
           and Metabolites

    • Free pre-print version: Loading...

      Authors: Meertens; Marinda; de Vries, Niels; Rosing, Hilde; Steeghs, Neeltje; Beijnen, Jos H.; Huitema, Alwin D. R.
      Abstract: imageBackground: Volumetric Absorptive Microsampling (VAMS) is a useful tool for therapeutic drug monitoring (TDM) of oral targeted anticancer agents. VAMS aims to improve safety and efficacy by enabling at-home blood sample collection by patients. This study aimed to develop and validate an ultra-high performance liquid chromatography–tandem mass spectrometry method for the quantitative determination of abiraterone, alectinib, cabozantinib, imatinib, olaparib, sunitinib, and the metabolites, Δ(4)-abiraterone (D4A), alectinib-M4, imatinib-M1, and N-desethyl sunitinib, in dried whole blood samples using VAMS to support TDM.Methods: After the collection of 10 μL of whole blood sample using the VAMS device, the analytes were extracted from the tip using methanol with shaking, evaporated, and reconstituted in acetonitrile:0.1 mol/L ammonium hydroxide in water (1:1, vol/vol). The extracts were then analyzed using ultra-high performance liquid chromatography–tandem mass spectrometry. Validation experiments based on the ICH M10 guideline were carried out, and stability was evaluated under shipping and storage conditions. VAMS specimens were collected in the outpatient clinic to demonstrate the applicability of the assay.Results: The validated range of the method was considered accurate and precise for all analytes. Accordingly, the validation experiments met the relevant requirements, except for cross-analyte interference. Based on the stability data, shipment can be performed at room temperature within 14 days after sample collection and the VAMS specimen can be stored up to 9 months at −20 and −70°C. Samples from 59 patients were collected at the hospital.Conclusions: The developed method could be used to successfully quantify the concentrations of abiraterone, D4A, alectinib, alectinib-M4, cabozantinib, imatinib, imatinib-M1, olaparib, sunitinib, and N-desethyl sunitinib within the validated range using VAMS. Therefore, the method can be used to estimate the dried whole blood-to-plasma ratios for TDM in the clinic.
      PubDate: Tue, 30 Jan 2024 00:00:00 GMT-
       
  • Factors Influencing Plasma Concentrations of Valproic Acid in Pediatric
           Patients With Epilepsy and the Clinical Significance of CYP2C9 Genotypes
           in Personalized Valproic Acid Therapy

    • Free pre-print version: Loading...

      Authors: Ma; Bingsuo; Yang, Kun; Li, Xinping; Su, Ning; Yu, Ting; Zou, Yan; Xu, Xingmeng; Wang, Fei; Cheng, Jingdong; Yan, Zijun; Chen, Tong; Zhang, Liangming
      Abstract: imageBackground: The aim of this study was to investigate the factors affecting plasma valproic acid (VPA) concentration in pediatric patients with epilepsy and the clinical significance of CYP2C9 gene polymorphisms in personalized dosing using therapeutic drug monitoring and pharmacogenetic testing.Methods: The medical records of children with epilepsy who underwent therapeutic drug monitoring at our institution between July 2022 and July 2023 and met the inclusion criteria were reviewed. Statistical analysis was performed to determine whether age, sex, blood ammonia, liver function, kidney function, and other characteristics affected the concentration-to-dose ratio of VPA (CDRV) in these patients. To investigate the effect of CYP2C9 polymorphisms on CDRV, DNA samples were collected from patients and the CYP2C9 genotypes were identified using real-time quantitative PCR.Results: The mean age of 208 pediatric patients with epilepsy was 5.50 ± 3.50 years. Among these patients, 182 had the CYP2C9 *1/*1 genotype, with a mean CDRV (mcg.kg/mL.mg) of 2.64 ± 1.46, 24 had the CYP2C9 *1/*3 genotype, with a mean CDRV of 3.28 ± 1.74, and 2 had the CYP2C9 *3/*3 genotype, with a mean CDRV of 6.46 ± 3.33. There were statistical differences among these 3 genotypes (P < 0.05). The CDRV in these patients were significantly influenced by age, aspartate aminotransferase, total bilirubin, direct bilirubin, globulin, albumin/globulin ratio, prealbumin, creatinine, and CYP2C9 polymorphisms. In addition, multivariate linear regression analysis identified total bilirubin, direct bilirubin, and CYP2C9 polymorphisms as independent risk factors for high CDRV.Conclusions: Liver problems and mutations in the CYP2C9 gene increase VPA levels. This underscores the importance of considering these factors when prescribing VPA to children with epilepsy, thereby enhancing the safety and efficacy of the therapy.
      PubDate: Fri, 26 Jan 2024 00:00:00 GMT-
       
  • Development, Validation, and Clinical Application of an
           Ultra–High-Performance Liquid Chromatography Coupled With Tandem Mass
           Spectrometry Method for the Determination of 10 Antituberculosis Drugs in
           Human Serum

    • Free pre-print version: Loading...

      Authors: Fan; Xudong; Guo, Suhang; Zhang, Ruoying; Cai, Qingshan; Lang, Yazhen; Huang, Jinpeng; Chen, Yuanyuan; Zhang, Ying; Xu, Yingying; Chen, Meng; Yang, Gaoyi; Cai, Xinjun
      Abstract: imageIntroduction: Linezolid, moxifloxacin, rifapentine, rifabutin, cycloserine, clofazimine, bedaquiline, levofloxacin, prothionamide, and ethionamide are commonly used second-line antituberculosis (anti-TB) drugs. To support therapeutic drug monitoring in regular clinical practice, the authors sought to develop a method based on ultra–high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS) that would allow for the simultaneous quantification of multiple second-line anti-TB drugs in human serum.Methods: Analytes were extracted from human serum by protein precipitation. UHPLC-MS/MS was performed using a gradient at a flow rate of 0.3 mL/min, and each sample was taken for 7.5 minutes. The mass spectrometry scanning mode used was electrospray ionization with multiple reaction monitoring in the positive mode.Results: Validation showed that endogenous substances in the sample did not interfere with the assay, and the relationship between X and Y was highly linear, with a coefficient of determination (R2)>0.9954 for each curve. The accuracy (85.0%–114.7%) and precision (intraday: 0.27%–9.32%; interday: 0.20%–7.66%) were less than 15.0%, and the internal standard-normalized matrix effects were consistent (coefficient of variation ≤4.40%). The analytes were stable in the final extract and human serum under various storage conditions (recovery: 87.0%–115.0%). The clinical applicability of the method was demonstrated by quantitative determination of analytes in serum samples obtained from patients with TB. Reproducibility of the drug concentrations measured in clinical samples was confirmed by incurred sample reanalysis.Conclusions: A simple and reliable analytical method was developed and validated for the simultaneous determination of 10 anti-TB drugs in human serum using UHPLC-MS/MS. Quantitation of anti-TB drugs in clinical samples confirmed that the assay is suitable for therapeutic drug monitoring in regular clinical practice.
      PubDate: Wed, 24 Jan 2024 00:00:00 GMT-
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 3.235.182.206
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-
JournalTOCs
 
 

 A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

        1 2 3 | Last   [Sort alphabetically]   [Restore default list]

  Subjects -> PHARMACY AND PHARMACOLOGY (Total: 575 journals)
Showing 1 - 200 of 253 Journals sorted by number of followers
Nature Reviews Drug Discovery     Full-text available via subscription   (Followers: 352)
Journal of Clinical Oncology     Hybrid Journal   (Followers: 260)
International Journal of Drug Policy     Hybrid Journal   (Followers: 241)
Journal of Medicinal Chemistry     Hybrid Journal   (Followers: 167)
Drugs     Full-text available via subscription   (Followers: 146)
Journal of Pharmaceutical Sciences     Hybrid Journal   (Followers: 140)
Advanced Drug Delivery Reviews     Hybrid Journal   (Followers: 95)
European Journal of Pharmaceutical Sciences     Hybrid Journal   (Followers: 84)
Drug Safety     Full-text available via subscription   (Followers: 81)
Pharmaceutical Research     Hybrid Journal   (Followers: 69)
Drug Discovery Today     Full-text available via subscription   (Followers: 63)
Biomaterials     Hybrid Journal   (Followers: 54)
Annals of Pharmacotherapy     Hybrid Journal   (Followers: 52)
Clinical Pharmacology & Therapeutics     Hybrid Journal   (Followers: 31)
Pharmacoepidemiology and Drug Safety     Hybrid Journal   (Followers: 29)
AAPS Journal     Hybrid Journal   (Followers: 29)
Annual Review of Pharmacology and Toxicology     Full-text available via subscription   (Followers: 27)
Journal of Pain & Palliative Care Pharmacotherapy     Hybrid Journal   (Followers: 26)
Regulatory Toxicology and Pharmacology     Hybrid Journal   (Followers: 26)
British Journal of Clinical Pharmacology     Hybrid Journal   (Followers: 25)
Journal of Controlled Release     Hybrid Journal   (Followers: 25)
Drug Development and Industrial Pharmacy     Hybrid Journal   (Followers: 25)
International Journal of Pharmacy Practice     Full-text available via subscription   (Followers: 24)
European Journal of Pharmaceutics and Biopharmaceutics     Hybrid Journal   (Followers: 23)
International Journal of Pharmaceutics     Hybrid Journal   (Followers: 23)
Journal of Clinical Psychopharmacology     Hybrid Journal   (Followers: 23)
Journal of Pharmacy and Pharmacology     Full-text available via subscription   (Followers: 23)
Critical Reviews in Toxicology     Hybrid Journal   (Followers: 22)
PharmacoEconomics     Full-text available via subscription   (Followers: 21)
American Journal of Cardiovascular Drugs     Hybrid Journal   (Followers: 20)
Chemical Research in Toxicology     Hybrid Journal   (Followers: 20)
Trends in Pharmacological Sciences     Full-text available via subscription   (Followers: 17)
Clinical Toxicology     Hybrid Journal   (Followers: 17)
Clinical Pharmacokinetics     Full-text available via subscription   (Followers: 16)
Critical Reviews in Clinical Laboratory Sciences     Hybrid Journal   (Followers: 16)
Journal of Natural Products     Hybrid Journal   (Followers: 16)
Journal of Pharmacokinetics and Pharmacodynamics     Hybrid Journal   (Followers: 16)
Toxicology and Applied Pharmacology     Hybrid Journal   (Followers: 16)
Pharmaceutical Development and Technology     Hybrid Journal   (Followers: 16)
Journal of Applied Toxicology     Hybrid Journal   (Followers: 15)
Psychopharmacology     Hybrid Journal   (Followers: 15)
Journal of Clinical Pharmacy and Therapeutics     Hybrid Journal   (Followers: 14)
Journal of Oncology Pharmacy Practice     Hybrid Journal   (Followers: 14)
Journal of the American Pharmacists Association     Full-text available via subscription   (Followers: 14)
Toxicology     Hybrid Journal   (Followers: 14)
International Journal of Toxicology     Hybrid Journal   (Followers: 13)
Journal of Pharmaceutical and Biomedical Analysis     Hybrid Journal   (Followers: 13)
Journal of Pharmacy Practice     Hybrid Journal   (Followers: 13)
Biopharmaceutics and Drug Disposition     Hybrid Journal   (Followers: 12)
Cardiovascular Drugs and Therapy     Hybrid Journal   (Followers: 12)
Clinical Trials     Hybrid Journal   (Followers: 12)
Toxicology Letters     Hybrid Journal   (Followers: 12)
Drug and Chemical Toxicology     Hybrid Journal   (Followers: 12)
American Journal of Therapeutics     Hybrid Journal   (Followers: 11)
Basic & Clinical Pharmacology & Toxicology     Hybrid Journal   (Followers: 11)
European Journal of Clinical Pharmacology     Hybrid Journal   (Followers: 11)
Journal of Psychopharmacology     Hybrid Journal   (Followers: 11)
Pharmacy Education     Full-text available via subscription   (Followers: 11)
Clinical Therapeutics     Hybrid Journal   (Followers: 10)
CNS Drugs     Full-text available via subscription   (Followers: 10)
Pharmaceutical Statistics     Hybrid Journal   (Followers: 10)
Seminars in Oncology Nursing     Full-text available via subscription   (Followers: 10)
Journal of Clinical Pharmacology     Hybrid Journal   (Followers: 10)
Toxicological Sciences     Hybrid Journal   (Followers: 10)
Advances in Pharmacological and Pharmaceutical Sciences     Open Access   (Followers: 10)
Biochemical Pharmacology     Hybrid Journal   (Followers: 9)
ChemMedChem     Hybrid Journal   (Followers: 9)
Drug Metabolism and Disposition     Hybrid Journal   (Followers: 9)
Drugs & Aging     Full-text available via subscription   (Followers: 9)
Drugs & Therapy Perspectives     Full-text available via subscription   (Followers: 9)
Medicinal Chemistry     Hybrid Journal   (Followers: 9)
Seminars in Hematology     Hybrid Journal   (Followers: 9)
Current Opinion in Pharmacology     Hybrid Journal   (Followers: 8)
Current Pharmaceutical Biotechnology     Hybrid Journal   (Followers: 8)
Drug Development Research     Hybrid Journal   (Followers: 8)
Epilepsy Research     Hybrid Journal   (Followers: 8)
European Neuropsychopharmacology     Hybrid Journal   (Followers: 8)
Food Additives & Contaminants Part A     Hybrid Journal   (Followers: 8)
Progress in Neuro-Psychopharmacology and Biological Psychiatry     Hybrid Journal   (Followers: 8)
Toxicology in Vitro     Hybrid Journal   (Followers: 8)
Inhalation Toxicology     Hybrid Journal   (Followers: 8)
Antiviral Research     Hybrid Journal   (Followers: 7)
Current Medicinal Chemistry     Hybrid Journal   (Followers: 7)
Drug Delivery     Open Access   (Followers: 7)
Environmental Toxicology and Pharmacology     Hybrid Journal   (Followers: 7)
Experimental and Clinical Psychopharmacology     Full-text available via subscription   (Followers: 7)
Frontiers in Drug Design & Discovery     Hybrid Journal   (Followers: 7)
Journal of Veterinary Pharmacology and Therapeutics     Hybrid Journal   (Followers: 7)
Prescriber     Hybrid Journal   (Followers: 7)
Toxicology Mechanisms and Methods     Hybrid Journal   (Followers: 7)
Journal of Pharmaceutical Innovation     Hybrid Journal   (Followers: 7)
AAPS PharmSciTech     Hybrid Journal   (Followers: 6)
Biometrical Journal     Hybrid Journal   (Followers: 6)
Clinical Drug Investigation     Full-text available via subscription   (Followers: 6)
Current Drug Delivery     Hybrid Journal   (Followers: 6)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry     Hybrid Journal   (Followers: 6)
Expert Review of Pharmacoeconomics & Outcomes Research     Full-text available via subscription   (Followers: 6)
Human & Experimental Toxicology     Hybrid Journal   (Followers: 6)
Toxicology and Industrial Health     Hybrid Journal   (Followers: 6)
Current Cancer Therapy Reviews     Hybrid Journal   (Followers: 5)
Current Drug Discovery Technologies     Hybrid Journal   (Followers: 5)
Anti-Infective Agents     Hybrid Journal   (Followers: 5)
Current Therapeutic Research     Open Access   (Followers: 5)
Reviews of Physiology, Biochemistry and Pharmacology     Hybrid Journal   (Followers: 5)
Expert Review of Anti-infective Therapy     Full-text available via subscription   (Followers: 5)
Expert Review of Molecular Diagnostics     Full-text available via subscription   (Followers: 5)
Fitoterapia     Hybrid Journal   (Followers: 5)
Journal of Pain Management & Medicine     Open Access   (Followers: 5)
Journal of Cardiovascular Pharmacology and Therapeutics     Hybrid Journal   (Followers: 5)
Journal of Separation Science     Hybrid Journal   (Followers: 5)
Scandinavian Journal of Clinical and Laboratory Investigation     Hybrid Journal   (Followers: 5)
Clinical Research and Regulatory Affairs     Hybrid Journal   (Followers: 5)
Pharmacogenomics Journal     Hybrid Journal   (Followers: 5)
ASSAY and Drug Development Technologies     Hybrid Journal   (Followers: 4)
BioDrugs     Full-text available via subscription   (Followers: 4)
Cancer Chemotherapy and Pharmacology     Hybrid Journal   (Followers: 4)
Current Pharmaceutical Design     Hybrid Journal   (Followers: 4)
Expert Review of Cardiovascular Therapy     Full-text available via subscription   (Followers: 4)
International Journal of Pharmaceutical and Healthcare Marketing     Hybrid Journal   (Followers: 4)
Pharmaceutical Medicine     Full-text available via subscription   (Followers: 4)
Journal of Child and Adolescent Psychopharmacology     Hybrid Journal   (Followers: 4)
Journal of Infection and Chemotherapy     Hybrid Journal   (Followers: 4)
Journal of Labelled Compounds and Radiopharmaceuticals     Hybrid Journal   (Followers: 4)
Journal of Pharmacology and Experimental Therapeutics     Hybrid Journal   (Followers: 4)
Neuropharmacology     Hybrid Journal   (Followers: 4)
Planta Medica     Hybrid Journal   (Followers: 4)
Immunopharmacology and Immunotoxicology     Hybrid Journal   (Followers: 4)
Physiology International     Full-text available via subscription   (Followers: 3)
Archiv der Pharmazie     Hybrid Journal   (Followers: 3)
BMC Pharmacology     Open Access   (Followers: 3)
Cardiovascular Therapeutics     Open Access   (Followers: 3)
Clinical and Experimental Pharmacology and Physiology     Hybrid Journal   (Followers: 3)
CNS Drug Reviews     Open Access   (Followers: 3)
Current Drug Metabolism     Hybrid Journal   (Followers: 3)
Current Pharmacogenomics and Personalized Medicine     Hybrid Journal   (Followers: 3)
Drug Resistance Updates     Hybrid Journal   (Followers: 3)
European Journal of Pharmacology     Hybrid Journal   (Followers: 3)
Frontiers in Medicinal Chemistry     Hybrid Journal   (Followers: 3)
Human Psychopharmacology Clinical and Experimental     Hybrid Journal   (Followers: 3)
Inflammation Research     Hybrid Journal   (Followers: 3)
Investigational New Drugs     Hybrid Journal   (Followers: 3)
Journal of Aerosol Medicine and Pulmonary Drug Delivery     Hybrid Journal   (Followers: 3)
Journal of Cardiovascular Pharmacology     Hybrid Journal   (Followers: 3)
Journal of Ethnopharmacology     Hybrid Journal   (Followers: 3)
Journal of Medical Marketing     Hybrid Journal   (Followers: 3)
Journal of Pharmacological and Toxicological Methods     Hybrid Journal   (Followers: 3)
Microbial Drug Resistance     Hybrid Journal   (Followers: 3)
International Journal of Neuropsychopharmacology     Open Access   (Followers: 3)
Therapeutic Drug Monitoring     Hybrid Journal   (Followers: 3)
Drug Metabolism Reviews     Hybrid Journal   (Followers: 3)
Acta Pharmacologica Sinica     Hybrid Journal   (Followers: 2)
Behavioural Pharmacology     Hybrid Journal   (Followers: 2)
Biomedicine & Pharmacotherapy     Full-text available via subscription   (Followers: 2)
Clinical Neuropharmacology     Hybrid Journal   (Followers: 2)
Current Drug Therapy     Hybrid Journal   (Followers: 2)
Current Enzyme Inhibition     Hybrid Journal   (Followers: 2)
Drugs in R & D     Full-text available via subscription   (Followers: 2)
Inflammopharmacology     Hybrid Journal   (Followers: 2)
Inpharma Weekly     Full-text available via subscription   (Followers: 2)
International Clinical Psychopharmacology     Hybrid Journal   (Followers: 2)
International Immunopharmacology     Hybrid Journal   (Followers: 2)
Letters in Drug Design & Discovery     Hybrid Journal   (Followers: 2)
Medicinal Research Reviews     Hybrid Journal   (Followers: 2)
Pharmacology & Therapeutics     Hybrid Journal   (Followers: 2)
Pharmacology Biochemistry and Behavior     Hybrid Journal   (Followers: 2)
Pharmacopsychiatry     Hybrid Journal   (Followers: 2)
Pulmonary Pharmacology & Therapeutics     Hybrid Journal   (Followers: 2)
Research in Social and Administrative Pharmacy     Hybrid Journal   (Followers: 2)
The Brown University Psychopharmacology Update     Hybrid Journal   (Followers: 2)
Toxicological & Environmental Chemistry     Hybrid Journal   (Followers: 2)
Toxicon     Hybrid Journal   (Followers: 2)
Journal of Microencapsulation: Microcapsules, Liposomes, Nanoparticles, Microcells, Microspheres     Hybrid Journal   (Followers: 2)
Canadian Journal of Physiology and Pharmacology     Hybrid Journal   (Followers: 1)
Current Neuropharmacology     Hybrid Journal   (Followers: 1)
Current Pharmaceutical Analysis     Hybrid Journal   (Followers: 1)
Current Vascular Pharmacology     Hybrid Journal   (Followers: 1)
Fundamental & Clinical Pharmacology     Hybrid Journal   (Followers: 1)
Journal of Drug Targeting     Hybrid Journal   (Followers: 1)
Journal of Inflammation     Open Access   (Followers: 1)
Journal of Neuroimmune Pharmacology     Hybrid Journal   (Followers: 1)
Journal of Texture Studies     Hybrid Journal   (Followers: 1)
Pharmacogenetics and Genomics     Hybrid Journal   (Followers: 1)
Particulate Science and Technology: An International Journal     Hybrid Journal   (Followers: 1)
Pharmaceutical Biology     Open Access  
Journal of Liposome Research     Hybrid Journal  
Vascular Pharmacology     Hybrid Journal  
Toxin Reviews     Hybrid Journal  
Kaohsiung Journal of Medical Sciences     Open Access  
Redox Report     Open Access  
Pharmacological Research     Hybrid Journal  
PharmacoEconomics & Outcomes News     Full-text available via subscription  
Pharmaceutical Chemistry Journal     Hybrid Journal  
NeuroMolecular Medicine     Hybrid Journal  
Journal of Ocular Pharmacology and Therapeutics     Hybrid Journal  
Harm Reduction Journal     Open Access  
Current Nanoscience     Hybrid Journal  
Infectious Disorders - Drug Targets     Hybrid Journal  
Current Bioactive Compounds     Hybrid Journal  
Cancer Biotherapy & Radiopharmaceuticals     Hybrid Journal  
Autonomic & Autacoid Pharmacology     Hybrid Journal  

        1 2 3 | Last   [Sort alphabetically]   [Restore default list]

Similar Journals
Similar Journals
HOME > Browse the 73 Subjects covered by JournalTOCs  
SubjectTotal Journals
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 3.235.182.206
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-